Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
Clinical trial NCT03761056 · COMPLETED
Trial details
- NCT number
- NCT03761056
- Sponsor
- Kite, A Gilead Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-29
- Primary completion
- 2023-10-12
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.